CClinicalTrials.gg
Sign In
Not yet recruitingNCT07346547REDCUREUpdated Jan 20, 2026

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

An observational study in CKD Anemia, sponsored by Nabiqasim Industries (Pvt) Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Nabiqasim Industries (Pvt) Ltd · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
384
Ages
18 Years and older
Sex
All
01

Study summary

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

02

Conditions studied

  • CKD Anemia

Keywords

  • Daprodustat
  • oral HIF PHI
  • CKD anemia
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients with Chronic Kidney Disease (CKD) anemia requiring anemia treatment

Inclusion criteria

  • Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)

    • Patients on hemodialysis (HD) or peritoneal dialysis (PD)
    • Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent

Exclusion criteria

Exclusion Criteria

  1. Acute Kidney Injury (AKI) without underlying chronicity
  2. Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
  3. Refusal or inability to provide consent
  4. Current enrollment in an interventional trial that restricts real-world data collection
  5. Life expectancy \< 3 months, where follow-up is not feasible
  6. Known contraindications to Daprodustat as per local prescribing information
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
384 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Daprodustat arm for CKD anemia patients

    Daprodustat arm for CKD anemia patients

    Drug: Daprodustat

Interventions

  • DrugDaprodustat

    Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

05

What researchers measure

Primary outcomes

  1. Serum hemoglobin levels

    Hemoglobin response to therapy

    Time frame: 3 months

Secondary outcomes

  1. Frequency of MACE ( Major Adverse Cardiovascular Events)

    MACE events: * Unstable angina requiring hospitalization * Non-fatal MI * Non-fatal stroke * Cardiovascular death * Other adverse events * Hospitalization episodes . Mortality * Optional patient-reported outcomes (fatigue, functional status)

    Time frame: 3 months

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07346547
Lead sponsor
Nabiqasim Industries (Pvt) Ltd
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jan 30, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jan 20, 2026

Study contacts

Hussain Abidi
Contact
NQmedicalaffairs@gmail.com
+923322583236

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Nabiqasim Industries (Pvt) Ltd

Start the discussion